Catalog No.
Product Name
Application
Product Information
Citations
-
neuropeptide Y Y2 receptor antagonist
JNJ-31020028 is a novel, selective, brain-penetrant neuropeptide Y Y2 receptor antagonist -
Endogenous galanin receptor agonist
Galanin (1-30) (human) is an endogenous peptide with multiple endocrine, metabolic and behavioral effects -
neuropeptide Y1 receptor antagonist
BMS-193885 is a potent, competitive neuropeptide (NPY) Y1 antagonist (Ki = 3.3 nM, IC50 = 5.9 nM) that displays > 47, > 100, > 160, > 160 and > 160-fold selectivity over ??1, α1, Y2, Y4 and Y5 receptors respectively. -
neuropeptide Y1 receptor antagonist
Y1 receptor antagonist 1 (H 409-22 isomer) is a neuropeptide Y1 receptor antagonist. -
neuropeptide Y5 receptor antagonist
CGP71683 hydrochloride is a competitive neuropeptide Y5 receptor antagonist with a Ki of 1.3 nM, and shows no obvious activity at Y1 receptor (Ki, >4000 nM) and Y2 receptor (Ki, 200 nM) in cell membranes. -
NPY Y5 receptor antagonist
Velneperit (S-2367) is a novel neuropeptide Y (NPY) Y5 receptor antagonist. - CART(55-102)(rat) is a rat satiety factor with potent appetite-suppressing activity. CART(55-102)(rat) is closely associated with leptin and neuropeptide Y. CART(55-102)(rat) can induces anxiety and stress-related behavior.
-
neuropeptide Y (NPY) Y5 receptor agonist
[D-Trp34]-Neuropeptide Y is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y markedly increases food intake in rats. -
NPRs Agonist
Nesiritide, a recombinant form of human B-type natriuretic peptide, primarily functions as an agonist of natriuretic peptide receptors (NPRs), specifically NPR-A and NPR-C, with affinity constants of 7.3 pM and 13 pM, respectively. It effectively regulates the activation and inactivation of L-type calcium channels, resulting in significant vasodilatory, diuretic, and natriuretic effects. Nesiritide is utilized in research on cardiovascular diseases, particularly in models of heart failure and vascular remodeling following arterial injury. -
NPY Y1/NPFF Receptor Antagonist
BIBP3226 is a selective antagonist of the neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptors, exhibiting K_i values of 1.1 nM, 79 nM, and 108 nM for rat NPY Y1, human NPFF2, and rat NPFF, respectively. This compound has demonstrated anxiogenic-like effects, making it a valuable tool for research in neuropharmacology, particularly in studies exploring anxiety-related disorders and the modulation of neuropeptide signaling pathways. -
NPY Y5 antagonist
S 25585 is a selective antagonist of the neuropeptide Y (NPY) Y5 receptor. This compound is primarily utilized in research focused on appetite regulation, demonstrating a significant ability to reduce food intake without directly blocking the Y5 receptor. Its unique mechanism makes it an essential tool for studying the intricate pathways involved in energy homeostasis and metabolic disorders. -
NPY-5 Receptor Antagonist
Neuropeptide Y5 receptor ligand-1 is a potent antagonist of the neuropeptide Y5 (NPY-5) receptor. This carbazole derivative is utilized in research applications focused on the role of NPY-5 in various physiological processes, including regulation of appetite, anxiety, and circadian rhythms. By inhibiting NPY-5 receptor activity, it provides valuable insights into neuropeptide signaling pathways and their implications in metabolic and neurobehavioral disorders. -
NPY-5 Receptor Antagonist
NPY-5 receptor antagonist-1 is a potent antagonist of the neuropeptide Y5 (NPY-5) receptor, exhibiting a Ki value of less than 1 μM. This compound is invaluable for investigating the roles of NPY-5 in obesity, feeding disorders, and various neurological conditions. Its ability to modulate NPY-5 receptor activity makes it a useful tool in pharmacological research and drug development related to metabolic and neuropsychiatric disorders. -
NPY Y5 Receptor Agonist
(D-Trp32)-Neuropeptide Y (porcine) is a selective agonist of the neuropeptide Y (NPY) Y5 receptor. It exhibits orexigenic activity, thereby promoting increased food intake, and has been shown to inhibit Forskolin-stimulated cAMP formation. This peptide is valuable for research focusing on appetite regulation and metabolic disorders. -
NPY Y1 Receptor Antagonist
BVD 10 is a highly selective antagonist of the neuropeptide Y (NPY) Y1 receptor. This compound effectively inhibits NPY-induced increases in glutamate levels, providing insights into neurochemical interactions. BVD 10 is particularly valuable for research focused on seizure mechanisms and related neurological studies. -
NPY Receptor Antagonist
BIIE-0246 dihydrochloride is a potent and highly selective non-peptide antagonist of the neuropeptide Y (NPY) Y2 receptor, exhibiting an IC50 value of 15 nM. This compound effectively inhibits NPY signaling, making it valuable for research on appetite regulation, neuroprotection, and anxiety-related disorders. BIIE-0246 dihydrochloride provides a robust tool for investigating the physiological roles of NPY and its involvement in various pathophysiological conditions. -
NPY Y2Antagonist
NPY Y2 Antagonist 2 is a selective inhibitor of the neuropeptide Y receptor Y2, exhibiting pKi values of 6.8 nM and 7.2 nM in human and rat brain tissues, respectively. This compound effectively blocks the NPY Y2-mediated negative feedback, leading to increased endogenous NPY release and enhanced activation of Y1 receptors. Its ability to penetrate the blood-brain barrier, along with moderate in vivo clearance and a favorable brain/plasma ratio, makes NPY Y2 Antagonist 2 a valuable tool for investigating mood disorders, alcohol withdrawal-related anxiety, and social anxiety linked to nicotine withdrawal. -
NPY5 Receptor Antagonist
SCH 430765 is a potent and selective antagonist of the neuropeptide Y5 (NPY5) receptor. This compound plays a significant role in modulating appetite and energy homeostasis, making it valuable for research into obesity and related metabolic disorders. Its ability to inhibit NPY5 receptor activity provides insights into potential therapeutic strategies for weight management and obesity-related conditions. -
NPY Y2 Antagonist
NPY Y2 Antagonist 1 is a selective antagonist of the neuropeptide Y receptor Y2 (NPY Y2), primarily functioning through competitive inhibition. This compound exhibits significant biological activity in modulating neuropeptide Y signaling pathways, making it invaluable for research focused on neurobiology and related therapeutic areas. Its application extends to studying the physiological roles of NPY receptors in various biological processes and potential implications in metabolic disorders and appetite regulation. -
NPY Y1 Receptor Antagonist
BIBO3304 is a selective antagonist of the neuropeptide Y (NPY) Y1 receptor, exhibiting subnanomolar affinity with IC50 values of 0.38 nM for the human receptor and 0.72 nM for the rat receptor. This compound serves as a valuable tool for investigating the role of NPY signaling in various biological processes, including appetite regulation and anxiety-related behaviors. Its oral bioavailability makes it suitable for in vivo studies in pharmacological research and neurobiology. -
NPY Y1/NPFF Receptor Antagonist
BIBP3226 TFA is a potent and selective antagonist of the neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptors. It exhibits inhibition constants (Kis) of 1.1 nM, 79 nM, and 108 nM for the rat NPY Y1, human NPFF2, and rat NPFF receptors, respectively. BIBP3226 TFA is utilized in research focused on anxiety and neuropeptide signaling pathways, providing valuable insights into the role of these receptors in various biological processes. -
NPY Y1 Receptor Agonist
[Leu31,Pro34]-Neuropeptide Y (porcine) is a selective agonist of the neuropeptide Y Y1 receptor. This analog exhibits significant anxiolytic effects, making it a valuable tool for studying anxiety-related disorders. It is predominantly utilized in neuropharmacological research to explore the role of NPY in stress and anxiety modulation. -
GalR2 Antagonist
M871 is a selective antagonist of the galanin receptor type 2 (GalR2), demonstrating a Ki value of 13.1 nM for GalR2, with significantly lower affinity for GalR1 and GalR3. This compound has been shown to reduce IgE production and the density of B cells in tissues, effectively alleviating allergic rhinitis in murine models. Additionally, M871 may impede nerve invasion in salivary adenoid cystic carcinoma and mitigate myocardial ischemia-reperfusion injury, making it a valuable tool for investigating GalR2-related conditions, including epilepsy and pain. -
NPY Receptor Y2 Agonist
Neuropeptide Y (3-36) (human, rat) is an agonist of the Neuropeptide Y receptor Y2 (NPY Y2). This neuropeptide Y metabolite, generated by the action of dipeptidyl peptidase-4 (DPP4), has been shown to reduce the release of norepinephrine through its interaction with the Y2 receptor. It is primarily utilized in research related to neurophysiology and metabolic disorders, providing insights into pathways associated with appetite regulation and anxiety. -
GAL2 Agonist
M1145 is a chimeric peptide that serves as a selective agonist for the galanin receptor type 2 (GAL2) with a Ki of 6.55 nM. This compound demonstrates over 90-fold increased affinity for GAL2 compared to GAL1 (Ki=587 nM) and 76-fold greater affinity relative to GalR3 (Ki=497 nM). M1145 enhances signal transduction pathways activated by galanin, making it a valuable tool for research on galanin receptor signaling and its implications in various biological processes. -
GAL1 Agonist
M617 is a selective galanin receptor 1 (GAL1) agonist, exhibiting inhibition constants (Kis) of 0.23 nM and 5.71 nM for GAL1 and GAL2, respectively. This compound primarily targets GAL1 to promote GLUT4 expression, significantly enhancing GLUT4 content in the cardiac muscle of type 2 diabetic rats. M617 is useful in research focused on metabolic disorders and the modulation of glucose homeostasis. -
NPY Y5 Receptor Antagonist
NTNCB hydrochloride is a selective antagonist of the neuropeptide Y Y5 receptor, exhibiting a Ki of 8 nM for human Y5. This compound is valuable for investigating the role of NPY signaling in various physiological processes and disorders. Its ability to specifically inhibit Y5 receptor activity makes it a useful tool in both pharmacological studies and drug discovery related to metabolic and neuropsychiatric diseases. -
Galanin receptor Antagonist
Galanin Receptor Ligand M35 is a high-affinity antagonist targeting the galanin receptor, exhibiting a dissociation constant (Kd) of 0.1 nM. This compound demonstrates Ki values of 0.11 nM for the human galanin receptor type 1 and 2.0 nM for type 2, making it an effective tool for studying the role of galanin receptors in various physiological and pathological processes. It is widely applicable in research focused on neurobiology, pain modulation, and neuroendocrine regulation. -
Satiety Factor
CART(55-102)(human) is an endogenous peptide that acts as a satiety factor, effectively suppressing appetite. It is intricately linked with the regulation of energy balance through its interactions with leptin and neuropeptide Y. This reagent is valuable for research applications focused on obesity, appetite control, and metabolic disorders. -
NPYY2 Receptor Antagonist
CYM 9484 is a selective neuropeptide Y (NPY) Y2 receptor antagonist, demonstrating high potency with an IC50 value of 19 nM. This compound effectively inhibits Y2 receptor activity, making it a valuable tool for studying neuropeptide signaling pathways and the role of NPY in various physiological processes. CYM 9484 is relevant for research in neurobiology and metabolic disorders where modulation of the Y2 receptor may provide therapeutic insights. -
NPY Y2 Receptor Antagonist
SF 11 is a potent antagonist of the neuropeptide Y Y2 receptor, exhibiting an IC50 value of 199 nM. This compound demonstrates antidepressant-like activity, making it a valuable tool for research into mood disorders and neuropharmacology. Its ability to penetrate the blood-brain barrier enhances its application in studies related to central nervous system functions and therapeutic interventions. -
Galanin Receptor Agonist
Galnon TFA is a selective non-peptide agonist of the galanin GAL1 and GAL2 receptors, exhibiting binding affinities with Kis of 11.7 μM and 34.1 μM, respectively. This compound demonstrates notable anticonvulsant and anxiolytic properties, making it valuable for research applications involving neurological disorders and the modulation of anxiety. Galnon TFA serves as an important tool for studying the therapeutic potential of galanin receptor signaling in various biological contexts. -
NPY2R Agonist
Nisotirostide is a selective NPY2 receptor agonist that mimics the action of peptide YY (PYY). This compound has demonstrated the ability to inhibit appetite, making it a valuable tool for researching obesity and metabolic disorders such as diabetes. Its application in these areas may provide insights into therapeutic strategies for appetite regulation and weight management. -
NPY Y5 Receptor Antagonist
NPY5RA-972 is a potent and selective antagonist of the neuropeptide Y (NPY) Y5 receptor, effectively penetrating the central nervous system (CNS). This compound inhibits the feeding behavior mediated by NPY Y5 receptor activation, making it a valuable tool for research into appetite regulation and obesity-related studies. Its oral bioavailability further enhances its utility for in vivo applications in neuroscience and metabolic research. -
Human Galanin Fragment
Galanin (1-19), human is the bioactive fragment of the human neuropeptide galanin. This peptide plays a critical role in various physiological processes, including the regulation of hormone release, pain modulation, and the alteration of feeding behavior. Its diverse biological activities make it a valuable tool for research applications in neurobiology, endocrinology, and metabolic studies. -
Y2R Antagonist
SF-22 is a potent antagonist of the neuropeptide Y receptor (Y2R), exhibiting an IC50 value of 750 nM. This compound effectively penetrates the blood-brain barrier, making it relevant for investigations into neurological diseases. Its ability to modulate Y2R activity provides valuable insights into neurobiological processes and potential therapeutic applications. -
NPY Cardiac Receptor Antagonist
Neuropeptide Y (18-36) (porcine) serves as a competitive antagonist of neuropeptide Y (NPY) cardiac receptors. With an IC50 value of 158 nM and a Ki value of 140 nM, this compound effectively inhibits the binding of I-NPY to cardiac ventricular membranes in a concentration-dependent manner. It is a valuable reagent for research focused on the pathophysiology and therapeutic interventions in congestive heart failure. -
Galanin Receptor Antagonist
Galantide serves as a non-specific antagonist of galanin receptors, comprised of peptides derived from galanin and substance P. It effectively recognizes two distinct classes of galanin binding sites in the rat hypothalamus, with dissociation constants (KD) of less than 0.1 nM and approximately 6 nM. Galantide demonstrates dose-dependent antagonism (IC50 = 1.0 nM) of galanin-mediated inhibition on glucose-induced insulin secretion in mouse pancreatic islets. Additionally, it binds to a singular population of substance P receptors with a KD of around 40 nM, demonstrating its potential for investigating galanin signaling pathways and their physiological effects.
